TruScreen trims FY2026 guidance as expansion costs weigh on earnings

TruScreen Group Ltd. ( (AU:TRU) ) just unveiled an announcement.

TruScreen Group has cut its FY2026 product revenue guidance to about NZ$2.4 million, up 41% on FY2025 but below prior market expectations, citing delayed payment under a signed Uzbekistan contract and a postponed follow-on order in Zimbabwe that has pushed some sales into FY2027. Total revenue is now expected to reach roughly NZ$2.7 million, while the group anticipates a loss similar to last year at around NZ$2.2 million as it absorbs higher market access and distribution costs amid expansion in Uzbekistan, India, Indonesia and select African markets.

Management frames these investments, together with fresh clinical validation from a large 15,000-patient COGA study in China, as building critical mass for wider adoption of its AI-enabled cervical screening technology and a path toward medium-term profitability. The updated guidance underscores TruScreen’s focus on long-term market positioning in emerging and developing healthcare systems, even as near-term earnings remain under pressure and shortfalls versus earlier expectations may weigh on investor sentiment.

More about TruScreen Group Ltd.

TruScreen Group Ltd. is a medical device company focused on cervical cancer screening, offering an AI-enabled device, TruScreen Ultra, that detects cervical tissue abnormalities in real time through optical and electrical measurements. Its CE-marked and ISO 13485-compliant technology is approved or registered in multiple major markets, including China, Australia, the U.K., Russia, Saudi Arabia, Mexico, Vietnam and others, with a growing installed base and over 200,000 examinations performed in FY2024.

Average Trading Volume: 878,048

Technical Sentiment Signal: Sell

Current Market Cap: A$11.35M

For detailed information about TRU stock, go to TipRanks’ Stock Analysis page.